Page 9 - reflections_dyslipidaemia_newsletter5_2023

REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #5 2023

The authors discuss that the results demonstrated here,
along with other similar studies, reinforce the more recent CLINICAL PEARLS FROM THE FACULTY Dyslipidaemia
dyslipidaemia guidelines and statements by the ESC, EAS, and
ACC that recommend a goal of achieving an LDL-C <55 mg/dL
in very high-risk patients and considering an LDL-C <40 mg/dL
in those with recurrent CV events. They go on to suggest that
targeting LDL-C <40 mg/dL might be extended to those patients
without recurrent events.

WATCH
PROF. SHAWKY DISCUSS THE
CLINICAL RELEVANCE OF AIMING FOR
VERY LOW LDL-C IN PATIENTS WITH
DYSLIPIDAEMIA.

CLICK HERE
FOR THE LINK TO FULL ARTICLE

SPECIAL POPULATION – FAMILIAL HYPERCHOLESTEROLAEMIA

2023 Update on European Atherosclerosis Society Consensus Statement on

Homozygous Familial Hypercholesterolaemia: New treatments and clinical guidance.
Cuchel M, et al. Eur Heart J. 2023 Jul 1;44(25):2277-2291.

Homozygous familial hypercholesterolaemia (HoFH) is a rare, provides updated diagnostic criteria, new insights on the
autosomal disease that is characterized by elevated levels of genetics of HoFH, updated recommendations on screening
LDL-C from conception and results in accelerated ASCVD and strategies for early detection, updated recommendations for
often early death. Underdiagnosis and undertreatment of HoFH cardiac work-up at diagnosis and follow-up, updated treatment
are ongoing issues, with recent estimates that ~30,000 people algorithm incorporating novel treatments, and updated guidance
worldwide have HoFH, but <5% are identified. on family planning for HoFH women of child-bearing potential
and heterozygous FH parents.
The 2023 update on the previous 2014 European
Atherosclerosis Society (EAS) consensus statement on HoFH

TABLE OF CONTENTS